Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alkermes Plc (NQ: ALKS )

29.46 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 29.46
Bid (Size) 22.00 (4)
Ask (Size) 30.62 (1)
Prev. Close 29.46
Today's Range 29.46 - 29.46
52wk Range 21.75 - 32.23
Shares Outstanding 166,121,384
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Sarissa Urges Alkermes Shareholders to Vote the Universal Blue Card to Upgrade Alkermes for the Benefit of Shareholders
From Sarissa Capital Management LP
Via Business Wire
Alkermes Earnings Perspective: Return On Capital Employed
 
Via Benzinga

Performance

YTD
+13.88%
+13.88%
1 Month
-4.69%
-4.69%
3 Month
+8.23%
+8.23%
6 Month
+15.48%
+15.48%
1 Year
+3.95%
+3.95%

More News

Read More
Analyst Expectations for Alkermes's Future
Via Benzinga
The Latest Analyst Ratings for Alkermes
Via Benzinga
A Preview Of Alkermes's Earnings
Via Benzinga
Alkermes Stock Sees Rising Relative Strength Rating
Via Investor's Business Daily
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
Via InvestorPlace
Earnings Scheduled For February 16, 2023
Via Benzinga
Alkermes Earnings Preview
Via Benzinga
Alkermes: Commercialization Program On Track, Sales Coming In Strong
Via Talk Markets
Alkermes Stock Sees Rising Relative Price Strength
Via Investor's Business Daily
Seattle Genetics' 'Refreshing' Enthusiasm Drives Stock Surge; Alkermes Briefly Breaks Out
Via Investor's Business Daily
Analyst Ratings for Alkermes
Via Benzinga
Alkermes's Return On Capital Employed Insights
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 3, 2022
Via Benzinga
Alkermes Plans Separating Its Oncology Unit; Lifts FY22 Earnings Guidance
Via Benzinga
Recap: Alkermes Q2 Earnings
Via Benzinga
Recap: Alkermes Q3 Earnings
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2022
Via Benzinga
Domino's Pizza To Rally 20%? Here Are 5 Other Price Target Changes For Friday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 16, 2022
Via Benzinga
Looking Into Alkermes's Return On Capital Employed
Via Benzinga
Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy
Via Benzinga
Earnings Preview: Alkermes
Via Benzinga
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.